143 related articles for article (PubMed ID: 34308856)
21. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
22. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
Jia WD; Xu GL; Xu RN; Sun HC; Wang L; Yu JH; Wang J; Li JS; Zhai ZM; Xue Q
J Cancer Res Clin Oncol; 2003 Jun; 129(6):327-34. PubMed ID: 12811549
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
24. Sulforaphane inhibits TGF-β-induced epithelial-mesenchymal transition of hepatocellular carcinoma cells via the reactive oxygen species-dependent pathway.
Wu J; Han J; Hou B; Deng C; Wu H; Shen L
Oncol Rep; 2016 May; 35(5):2977-83. PubMed ID: 26935987
[TBL] [Abstract][Full Text] [Related]
25. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
[TBL] [Abstract][Full Text] [Related]
26. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma.
Meng J; Sun B; Zhao X; Zhang D; Zhao X; Gu Q; Dong X; Zhao N; Liu P; Liu Y
Mol Cancer Ther; 2014 Dec; 13(12):3107-22. PubMed ID: 25277383
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of acriflavine in human hepatocellular carcinoma cells.
Lee CJ; Yue CH; Lin YY; Wu JC; Liu JY
Anticancer Res; 2014 Jul; 34(7):3549-56. PubMed ID: 24982368
[TBL] [Abstract][Full Text] [Related]
28. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Zhu XD; Zhang JB; Fan PL; Xiong YQ; Zhuang PY; Zhang W; Xu HX; Gao DM; Kong LQ; Wang L; Wu WZ; Tang ZY; Ding H; Sun HC
BMC Cancer; 2011 Jan; 11():28. PubMed ID: 21251271
[TBL] [Abstract][Full Text] [Related]
30. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo.
Lu HY; Chu HX; Tan YX; Qin XC; Liu MY; Li JD; Ren TS; Zhang YS; Zhao QC
Life Sci; 2020 Mar; 244():117343. PubMed ID: 31978449
[TBL] [Abstract][Full Text] [Related]
31. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY
World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216
[TBL] [Abstract][Full Text] [Related]
32. UNC119 promoted cell growth and migration by Wnt/β-catenin signal and TGF-β/EMT signal pathway in hepatocellular carcinoma.
Liu ZH; Zhang YF; Xu ZD; Z H L; Y F Z; Z D X
J BUON; 2018; 23(6):1717-1724. PubMed ID: 30610799
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
34. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
35. [Effect of lupeol on invasion and metastasis of human hepatoma HepG2 and SK-HEP-1 cells and its mechanism].
Liu BJ; Ning Q; Zhong RL; Xia Z; Jiang ZY; Song J; Wei YJ
Zhongguo Zhong Yao Za Zhi; 2020 Dec; 45(24):6028-6035. PubMed ID: 33496144
[TBL] [Abstract][Full Text] [Related]
36. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
37. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS
Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254
[TBL] [Abstract][Full Text] [Related]
38. I
Wu L; Sun B; Lin X; Liu C; Qian H; Chen L; Yang Y; Shen F; Su C
Genes Cells; 2018 Jan; 23(1):35-45. PubMed ID: 29210217
[TBL] [Abstract][Full Text] [Related]
39. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
40. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
